775 related articles for article (PubMed ID: 16453012)
1. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis.
Cully M; You H; Levine AJ; Mak TW
Nat Rev Cancer; 2006 Mar; 6(3):184-92. PubMed ID: 16453012
[TBL] [Abstract][Full Text] [Related]
2. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
3. PTEN expression and function in adult cancer stem cells and prospects for therapeutic targeting.
Ciuffreda L; Falcone I; Incani UC; Del Curatolo A; Conciatori F; Matteoni S; Vari S; Vaccaro V; Cognetti F; Milella M
Adv Biol Regul; 2014 Sep; 56():66-80. PubMed ID: 25088603
[TBL] [Abstract][Full Text] [Related]
4. PI3K/PTEN signaling in tumorigenesis and angiogenesis.
Jiang BH; Liu LZ
Biochim Biophys Acta; 2008 Jan; 1784(1):150-8. PubMed ID: 17964232
[TBL] [Abstract][Full Text] [Related]
5. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.
Carnero A; Blanco-Aparicio C; Renner O; Link W; Leal JF
Curr Cancer Drug Targets; 2008 May; 8(3):187-98. PubMed ID: 18473732
[TBL] [Abstract][Full Text] [Related]
6. Posttranslational Regulation and Conformational Plasticity of PTEN.
Kotelevets L; Trifault B; Chastre E; Scott MGH
Cold Spring Harb Perspect Med; 2020 Jul; 10(7):. PubMed ID: 31932468
[TBL] [Abstract][Full Text] [Related]
7. PTEN/PTENP1: 'Regulating the regulator of RTK-dependent PI3K/Akt signalling', new targets for cancer therapy.
Haddadi N; Lin Y; Travis G; Simpson AM; Nassif NT; McGowan EM
Mol Cancer; 2018 Feb; 17(1):37. PubMed ID: 29455665
[TBL] [Abstract][Full Text] [Related]
8. PTEN and the PI3-kinase pathway in cancer.
Chalhoub N; Baker SJ
Annu Rev Pathol; 2009; 4():127-50. PubMed ID: 18767981
[TBL] [Abstract][Full Text] [Related]
9. Targeting phosphoinositide 3-kinase: moving towards therapy.
Marone R; Cmiljanovic V; Giese B; Wymann MP
Biochim Biophys Acta; 2008 Jan; 1784(1):159-85. PubMed ID: 17997386
[TBL] [Abstract][Full Text] [Related]
10. The biology and clinical relevance of the PTEN tumor suppressor pathway.
Sansal I; Sellers WR
J Clin Oncol; 2004 Jul; 22(14):2954-63. PubMed ID: 15254063
[TBL] [Abstract][Full Text] [Related]
11. PTEN, more than the AKT pathway.
Blanco-Aparicio C; Renner O; Leal JF; Carnero A
Carcinogenesis; 2007 Jul; 28(7):1379-86. PubMed ID: 17341655
[TBL] [Abstract][Full Text] [Related]
12. P-REX2a driving tumorigenesis by PTEN inhibition.
Leslie NR
Sci Signal; 2009 Oct; 2(94):pe68. PubMed ID: 19861688
[TBL] [Abstract][Full Text] [Related]
13. Role of PTEN/PI3K pathway in endothelial cells.
Suzuki A; Hamada K; Sasaki T; Mak TW; Nakano T
Biochem Soc Trans; 2007 Apr; 35(Pt 2):172-6. PubMed ID: 17371230
[TBL] [Abstract][Full Text] [Related]
14. The impact of PTEN regulation by CK2 on PI3K-dependent signaling and leukemia cell survival.
Barata JT
Adv Enzyme Regul; 2011; 51(1):37-49. PubMed ID: 21035501
[TBL] [Abstract][Full Text] [Related]
15. The tumour suppressor PTEN mediates a negative regulation of the E3 ubiquitin-protein ligase Nedd4.
Ahn Y; Hwang CY; Lee SR; Kwon KS; Lee C
Biochem J; 2008 Jun; 412(2):331-8. PubMed ID: 18307411
[TBL] [Abstract][Full Text] [Related]
16. PTEN mutation: many birds with one stone in tumorigenesis.
Liu W; Zhou Y; Reske SN; Shen C
Anticancer Res; 2008; 28(6A):3613-9. PubMed ID: 19189642
[TBL] [Abstract][Full Text] [Related]
17. Molecular pathways: intercellular PTEN and the potential of PTEN restoration therapy.
Hopkins BD; Parsons RE
Clin Cancer Res; 2014 Nov; 20(21):5379-83. PubMed ID: 25361917
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer, PI3K, PTEN and prognosis.
Wise HM; Hermida MA; Leslie NR
Clin Sci (Lond); 2017 Feb; 131(3):197-210. PubMed ID: 28057891
[TBL] [Abstract][Full Text] [Related]
19. The iron-regulated metastasis suppressor NDRG1 targets NEDD4L, PTEN, and SMAD4 and inhibits the PI3K and Ras signaling pathways.
Kovacevic Z; Chikhani S; Lui GY; Sivagurunathan S; Richardson DR
Antioxid Redox Signal; 2013 Mar; 18(8):874-87. PubMed ID: 22462691
[TBL] [Abstract][Full Text] [Related]
20. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia.
Steelman LS; Abrams SL; Whelan J; Bertrand FE; Ludwig DE; Bäsecke J; Libra M; Stivala F; Milella M; Tafuri A; Lunghi P; Bonati A; Martelli AM; McCubrey JA
Leukemia; 2008 Apr; 22(4):686-707. PubMed ID: 18337767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
